The medtech segment achieved operational revenue growth of 4.4% despite ongoing weaknesses in the Chinese market. Notably, ...

Baltimore settled with opioid manufacturer Johnson & Johnson on the eve of its trial against that company and two ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research ...

In a Sept. 17 letter, HRSA said it expects the pharmaceutical company to cease implementation of rebates to 340B hospitals. The potential consequences of not doing so include termination of its ...

After examining Johnson & Johnson, the following trends can be inferred: A Price to Earnings ratio of 24.93 significantly below the industry average by 0.75x suggests undervaluation. This can make the ...

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition ...

Baltimore City settled with Johnson & Johnson just before an opioid trial, with settlement details undisclosed.

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Johnson & Johnson (JNJ – Research Report). The ...

Identifying stocks to buy and hold for decades rather than months or years can be difficult. The world and the economy are constantly changing, creating risks for long-term investors.

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Antiphospholipid Syndrome.

As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their ...

Vanda pharmeucitals received a rejection for its drug tradipitant, causing the company management to criticize the FDA.